PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.41%
Negative revenue growth while CRVO stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-12.41%
Negative gross profit growth while CRVO is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-27.47%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-27.47%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-27.92%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-20.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-20.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
6.47%
Share change of 6.47% while CRVO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
6.47%
Diluted share change of 6.47% while CRVO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-21.90%
Negative OCF growth while CRVO is at 10.67%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-21.77%
Negative FCF growth while CRVO is at 10.67%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2645.13%
Negative 10Y OCF/share CAGR while CRVO stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
92.60%
5Y OCF/share CAGR is similar to CRVO's 98.92%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
85.56%
3Y OCF/share CAGR similar to CRVO's 94.87%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
-3055.33%
Negative 10Y net income/share CAGR while CRVO is at 99.99%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.82%
5Y net income/share CAGR similar to CRVO's 98.48%. Walter Schloss might see both on parallel mid-term trajectories.
82.14%
3Y net income/share CAGR 75-90% of CRVO's 93.99%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1796.75%
Positive growth while CRVO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-58.41%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
18.52%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-6.32%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-20.42%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
29.66%
R&D growth drastically higher vs. CRVO's 6.75%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
16.61%
SG&A growth well above CRVO's 5.08%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.